Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3794MR)

This product GTTS-WQ3794MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3794MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13360MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ7572MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ7411MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ13296MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ2662MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ2931MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ5187MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ1693MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW